Impact of Sustained Virologic Response on Glycemic Control Among Diabetic Patients With Hepatitis C Virus Related Liver Disease

Assiut University

Status: Unknown

Conditions: Hepatitis c

Study type: Observational

Funder types: Other

Identifiers

NCT03591783

HCVDM

Details and patient eligibility

About

Hepatitis C virus (HCV) is a major cause of chronic liver disease. The World Health Organization has reported that 170 million people are chronically infected with HCV globally. The highest prevalence of HCV infection worldwide exists in Egypt (15%); 90% of infection among Egyptian patients is due to genotype 4

Enrollment: 140 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Chronic HCV infection will be diagnosed based on positive testing for serum HCV RNA and anti-HCV Ab.
• Diagnosis of type 2 DM will depend on fasting level of serum glucose more than 126 mg/dl and/or serum level of HbA1c more than 6.5 % on oral hypoglycemic therapy.

Exclusion criteria

• Chronic hepatitis due to causes other than HCV infection
• Coinfection with HBV infection
• Hepatocellular carcinoma
• Child C stage of liver cirrhosis.
• Patients with type I diabetes mellitus.
• Cardiopulmonary diseases.
• Major illness.
• Patient receiving corticosteroids.
• Patient refused consent.

Trial design

140 participants in 1 patient group

study group

Description:

All patients will be subjected to: Baseline investigations, end of treatment investigations and 3 months after treatment investigations.